The duration of sulfonylurea treatment is associated with β-Cell dysfunction in patients with type 2 diabetes mellitus

Mi Seon Shin, Jee Hee Yu, Chang Hee Jung, Jenie Yoonoo Hwang, Woo Je Lee, Min Seon Kim, Joong Yeol Park

Research output: Contribution to journalArticlepeer-review

22 Citations (Scopus)


Background: This study investigated the incidence of β-cell dysfunction and the clinical and biochemical factors affecting that in patients with type 2 diabetes having more than 3 years of follow-up. Subjects and Methods: β-Cell dysfunction was assessed by measuring changes in the fasting serum C-peptide concentrations. Patients were classified into two groups: cases showing a decreased (Group D) or an unchanged or increased (Group I) C-peptide concentration from the baseline. Results: Of the 504 patients included in this study, 259 (51%) showed decreased C-peptide concentrations, of whom 20% showed a decrease of ≥50%. Most patients, however, had a final C-peptide concentration of ≥1ng/mL, with only 18 (4%) individuals having a level <0.6ng/mL. Patients in Group D had a longer duration of diabetes, higher initial hemoglobin A1c concentration, and longer treatment durations with sulfonylurea and insulin compared with Group I. After adjusting for diabetes duration and C-peptide follow-up period, the duration of sulfonylurea treatment was found to be the only factor independently associated with decreases in the C-peptide concentration. Conclusions: Although β-cell function deteriorates over time in patients with type 2 diabetes, these cases mainly have fasting serum C-peptide concentrations of ≥1ng/mL. A longer treatment duration with sulfonylurea is associated with a more rapid decline in the C-peptide concentration.

Original languageEnglish
Pages (from-to)1033-1042
Number of pages10
JournalDiabetes Technology and Therapeutics
Issue number11
Publication statusPublished - 2012 Nov 1

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Medical Laboratory Technology


Dive into the research topics of 'The duration of sulfonylurea treatment is associated with β-Cell dysfunction in patients with type 2 diabetes mellitus'. Together they form a unique fingerprint.

Cite this